The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
Randomised data will be needed to answer lingering questions about DKN-01.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.